Russia’s Skolkovo Foundation and AstraZeneca, a global biopharmaceutical company, are putting together a new joint acceleration program for projects that develop solutions for cancer therapy, cardiovascular diseases, metabolism and kidney problems, and respiratory diseases, Firrma.ru reported.
Primer Capital, a Russian venture fund with international presence, is acting as partner for the acceleration initiative.
The program will be aimed at identifying promising ideas and solutions to benefit the above-mentioned medical fields and also at addressing a range of specific problems in the existing healthcare system. Developing and promoting digital medicine solutions is also a goal for this year’s acceleration program.